References
- 1HallettMBlepharospasm: Recent advancesNeurology2002591306131212434791
- 2HallettMEvingerCJankovicJStacyMBEBRF International WorkshopUpdate on blepharospasm: report from the BEBRF International WorkshopNeurology2008711275128218852443
- 3KhooshnoodiMAFactorSAJinnahHASecondary blepharospasm associated with structural lesions of the brainJ Neurol Sci20133319810123747003
- 4EmotoYEmotoHOishiEHikitaSWakakuraMTwelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessationDrug, Healthc Patient Saf2011391421753898
- 5RanaAQKabirADoguOPatelAKhondkerSPrevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremorEur Neurol20126831832123075668
- 6BatlaAStamelouMBhatiaKPTreatment of focal dystoniaCurr Treat Options Neurol20121421322922415705
- 7TruongDDJostWHBotulinum toxin: clinical useParkinsonism Relat Disord20061233135516870487
- 8KanovskyPStreitovaHBaresMHortovaHTreatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: Evidence of a long-lasting effectMov Disord19991488688810495063
- 9JankovicJDisease-oriented approach to botulinum toxin useToxicon20095461462319073203
- 10BlitzerABotulinum toxin A and B: a comparative dosing study for spasmodic dysphoniaOtolaryngol Head Neck Surg200513383683816360499
- 11BusnerJTargumSDThe clinical global impressions scale: Applying a research tool in clinical practicePsychiatry (Edgmont)20074283720526405
- 12DefazioGLivreaPEpidemiology of primary blepharospasmMov Disord20021771211835433
- 13YoonWTChungEJLeeSHKimBJLeeWYClinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonismJ Clin Neurol2005115916520396463
- 14CzyzCNBurnsJAPetrieTPWatkinsJRCahillKVFosterJALong-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndromeAm J Ophthalmol2013156173177 e223541393
- 15AbabnehOHCetinkayaAKulwinDRLong-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasmClin Experiment Ophthalmol20144225426123844601
- 16MejiaNIVuongKDJankovicJLong-term botulinum toxin efficacy, safety, and immunogenicityMov Disord20052059259715645481
- 17Ramirez-CastanedaJJankovicJLong-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20-year follow-upToxicon20149034434825130293
- 18AinsworthJRKraftSPLong-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasmOphthalmology1995102203620409098314
- 19StreitovaHBaresMLong-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: Retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 yearsActa Neurol2014114285291
- 20KolleweKMohammadiBKohlerSPickenbrockHDenglerRDresslerDBlepharospasm: Long-term treatment with either Botox, Xeomin or DysportJ Neural Transm2014725[Epub ahead of print].
- 21SimpsonDMBlitzerABrashearAet alAssessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology2008701699170618458230
- 22JankovicJParkinson's disease: clinical features and diagnosisJ Neurol Neurosurg Psychiatry20087936837618344392
- 23RoggenkamperPJostWHBihariKComesGGrafeSTeam NTBSEfficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasmJ Neural Transm200611330331215959841
- 24EvidenteVGTruongDJankovicJComellaCLGrafeSHanschmannAIncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well toleratedJ Neurol Sci201434611612025186131